Merck & Co., Inc. rose in value as they boosted production of Keytruda, a groundbreaking anti-PD-1 therapy. The FDA approved Keytruda for use in adults with head and neck cancer, marking a significant milestone in cancer care. The company is also expanding its oncology pipeline with promising updates on various treatments.

To meet demand, Merck & Co., Inc. is constructing a $1 billion Biologics Center in Delaware. This facility will focus on next-gen biologics and serve as the U.S. manufacturing hub for Keytruda. This move will enhance supply chain resilience and boost production capacity for the innovative drug.

While Merck & Co., Inc. shows potential as an investment, some believe AI stocks offer greater upside and less risk. For those seeking an undervalued AI stock with promising growth potential, check out the free report on the best short-term AI stock. Explore other investment opportunities with our recommendations on stocks set to double in three years and hidden AI stocks to buy now.

Read more at Yahoo Finance: Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production